Skip to main content

Doug Ethell

Theme: Recycling poorly- recycled material
Topic: TBC
Date/Time: Aug 18th @ 2:30 PM

Dr. Doug Ethell completed a Ph.D. in Neurobiology at the University of British Columbia. He was a Human Frontiers of Science Long-Term Fellow at the Max Planck Institute before returning to the West Coast to work at the Scripps Research Institute. His interdisciplinary research group has worked on Alzheimer’s disease, Parkinson’s disease, MS, and autism, which resulted in two clinical trials of minocycline in patients with Fragile X syndrome–now used off-label by thousands of patients. Dr. Ethell’s team also ran a clinical study on Alzheimer’s specific T cell responses, establishing that women lose most of those responses around menopause. In 2015, he founded Leucadia Therapeutics based on his characterization of a mechanism critical to removing toxic metabolites from the human brain, which deteriorates with age. The solution is a tiny implantable device that restores this clearance mechanism and could reverse early Alzheimer’s disease and attenuate brain aging. The first cohort of patients will receive the device, called Arethusta, in early 2024.

For a recent interview with Dr. Ethell, see: